Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023GlobeNewsWire • 10/09/23
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous UrticariaGlobeNewsWire • 10/09/23
Jasper Therapeutics to Present New Positive Data on Briquilimab Conditioning in Patients with Fanconi Anemia at the 2023 Fanconi Anemia Research Fund Scientific SymposiumGlobeNewsWire • 09/21/23
Jasper Therapeutics to Present at the Cantor Fitzgerald 2023 Global Healthcare ConferenceGlobeNewsWire • 09/15/23
Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 08/11/23
Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeGlobeNewsWire • 06/22/23
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business UpdateGlobeNewsWire • 05/12/23
Jasper Therapeutics Announces Appointment of Matthew Ford as Vice President, Human ResourcesGlobeNewsWire • 04/13/23
Jasper Therapeutics Appoints David Hinds as Senior Vice President, Development OperationsGlobeNewsWire • 04/10/23
Jasper Therapeutics to Present at Cantor Fitzgerald's The Future of Oncology Virtual SymposiumGlobeNewsWire • 03/31/23
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical OfficerGlobeNewsWire • 03/23/23
Jasper Therapeutics Reports Fiscal 2022 Financial Results and Provides a Business UpdateGlobeNewsWire • 03/08/23
Jasper Therapeutics Appoints Industry Veteran Vishal Kapoor to its Board of DirectorsGlobeNewsWire • 02/17/23
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTRGlobeNewsWire • 02/17/23
Jasper Therapeutics Presents Data Supporting Ongoing Development of Briquilimab, its c-Kit Targeting Antibody, at the 2023 Transplantation & Cellular Therapy Meetings of the ASTCT and CIBMTRGlobeNewsWire • 02/17/23
Jasper Therapeutics Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Sickle Cell Disease PatientsGlobeNewsWire • 02/16/23